Leap Therapeutics Stock (NASDAQ:LPTX)
Previous Close
$2.25
52W Range
$0.62 - $4.79
50D Avg
$2.92
200D Avg
$2.70
Market Cap
$24.91M
Avg Vol (3M)
$413.38K
Beta
0.22
Div Yield
-
LPTX Company Profile
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
LPTX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HEPA | Hepion Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| MREO | Mereo BioPharma Group plc |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PDSB | PDS Biotechnology Corporation |
| XFOR | X4 Pharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| INZY | Inozyme Pharma, Inc. |
| ELEV | Elevation Oncology, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |